NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
31 trialsNCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05440942 2025-06-05
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
Phase 1 Completed
NCT03299088 2025-05-21
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
University of California, Davis
Phase 1 Completed
NCT04487106 2025-04-22
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03026517 2025-01-23
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT03434262 2024-05-31
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04967079 2024-04-23
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Shanghai Chest Hospital
Phase 1 Completed
NCT03317119 2024-04-08
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03516214 2024-02-15
EATON
University of Cologne
Phase 1 Completed
NCT02367859 2024-01-30
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Stanford University
Phase 2 Completed
NCT04059224 2023-09-26
TraMel-WT
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01740648 2023-09-18
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03714958 2023-09-13
TRAHD
Centre Leon Berard
Phase 1 Completed
NCT03428126 2023-06-15
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02428270 2022-11-01
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
NCT02399943 2022-05-16
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02296112 2021-05-28
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT03352947 2020-12-08
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01467310 2020-09-02
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01941927 2020-02-12
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
University of California, San Francisco
Phase 2 Completed
NCT02439411 2019-12-02
DEIS
Grupo Español Multidisciplinar de Melanoma
Completed
NCT02296996 2019-01-23
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01438554 2018-08-29
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02138292 2018-05-15
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01553851 2016-12-26
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed